Literature DB >> 25840090

A global perspective on the epidemiology of pulmonary hypertension.

Ana Olga Mocumbi1, Friedrich Thienemann2, Karen Sliwa3.   

Abstract

The epidemiology of pulmonary hypertension (PH) is not fully determined worldwide but is believed to vary in different regions of the world, with differences determined by genetic, geographic, environmental, and socioeconomic factors, as well as sex-related practices and inequities in access to health care. This article reviews the global epidemiology of PH, with emphasis on the prevalence, causes, forms, and underlying factors in the developing world. Left ventricular heart disease is the most common cause worldwide, but the main contributors in developing countries are chronic infectious diseases, hypertensive heart disease, cardiomyopathy, and rheumatic heart disease. Despite data suggesting a high prevalence in Sub-Saharan Africa, the available literature is very limited. International registries like the Pan African Pulmonary Hypertension Cohort are essential to provide information about the causes, comorbidities, and diagnostic classification, therapeutic management, and the natural course of PH worldwide. Moreover, there is a need to track diagnostic and management practices and challenges to identify the gaps and gradients between different regions of the world. The information gained will pinpoint areas for improvement, aiming at bridging the current divide between low-income and high-income countries.
Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25840090     DOI: 10.1016/j.cjca.2015.01.030

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  10 in total

Review 1.  Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa.

Authors:  Anastase Dzudie; Bonaventure Suiru Dzekem; Dike B Ojji; Andre Pascal Kengne; Ana Olga Mocumbi; Karen Sliwa; Friedrich Thienemann
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 2.  Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.

Authors:  Gerald J Maarman; Rainer Schulz; Karen Sliwa; Ralph Theo Schermuly; Sandrine Lecour
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

Review 3.  Pulmonary hypertension in developing countries: Limiting factors in time to diagnosis, specialised medications and contextualised recommendations.

Authors:  G J Maarman
Journal:  Afr J Thorac Crit Care Med       Date:  2022-05-05

4.  Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.

Authors:  Sophia Emmons-Bell; Catherine Johnson; Alexandra Boon-Dooley; Paul A Corris; Peter J Leary; Stuart Rich; Magdi Yacoub; Gregory A Roth
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

5.  The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis.

Authors:  Limin Zhang; Yujia Liu; Shuai Zhao; Zhen Wang; Miaomiao Zhang; Su Zhang; Xinzhuo Wang; Shuang Zhang; Wenyan Zhang; Liying Hao; Guangyu Jiao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-06-10

6.  Preventive aerobic training exerts a cardioprotective effect on rats treated with monocrotaline.

Authors:  Francis Lopes Pacagnelli; Ana Karênina Dias de Almeida Sabela; Katashi Okoshi; Thaoan Bruno Mariano; Dijon Henrique Salomé Campos; Robson Francisco Carvalho; Antônio Carlos Cicogna; Luiz Carlo Marques Vanderlei
Journal:  Int J Exp Pathol       Date:  2016-07-01       Impact factor: 1.925

7.  Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up.

Authors:  Anastase Dzudie; Bonaventure Suiru Dzekem; Cabral Tantchou Tchoumi; Leopold Ndemnge Aminde; Ana O Mocumbi; Martin Abanda; Friedrich Thienemann; Andre Pascal Kengne; Karen Sliwa
Journal:  Cardiovasc J Afr       Date:  2018-07-07       Impact factor: 1.167

8.  Lifestyle Modification Practice and Associated Factors Among Diagnosed Hypertensive Patients in Selected Hospitals in Central Gondar Zone.

Authors:  Moges Smachew; Melkitu Fentie Melak; Azeb Atenafu; Aysheshim Kassahun Belew
Journal:  Nutr Metab Insights       Date:  2022-03-23

9.  Prevalence and predictive value of electrocardiographic abnormalities in pulmonary hypertension: evidence from the Pan-African Pulmonary Hypertension Cohort (PAPUCO) study.

Authors:  Irina Balieva; Anastase Dzudie; Friedrich Thienemann; Ana O Mocumbi; Kamilu Karaye; Mahmoud U Sani; Okechukwu S Ogah; Adriaan A Voors; Andre Pascal Kengne; Karen Sliwa
Journal:  Cardiovasc J Afr       Date:  2017-10-11       Impact factor: 1.167

10.  Computational quantification of patient-specific changes in ventricular dynamics associated with pulmonary hypertension.

Authors:  Henrik Finsberg; Ce Xi; Xiaodan Zhao; Ju Le Tan; Martin Genet; Joakim Sundnes; Lik Chuan Lee; Liang Zhong; Samuel T Wall
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-11-01       Impact factor: 4.733

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.